Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 10,299	$ 29,163
Restricted cash	0	5,005
Marketable securities	32,754	25,917
Prepaid and other current assets	1,053	1,312
Total current assets	44,106	61,397
Property and equipment, net	165	257
Deferred tax assets	0	575
Other assets	309	1,722
Total assets	44,580	63,376
Liabilities
Accounts payable	762	1,343
Accrued liabilities	4,857	7,812
Notes payable, current	0	159
Total current liabilities	5,619	9,314
Other long-term liabilities	1,507	3,873
Total liabilities	7,126	13,187
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2018 and December 31, 2017, respectively	0	0
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,865,735 and 9,483,911 shares, at December 31, 2018 and December 31, 2017, respectively	10	9
Additional paid-in capital	436,433	433,044
Treasury stock, at cost; 11,080 shares at December 31, 2018 and December 31, 2017 respectively	(708)	(708)
Accumulated deficit	(397,977)	(381,810)
Accumulated other comprehensive loss	(32)	(28)
Total Caladrius Biosciences, Inc. stockholders' equity	37,726	50,507
Noncontrolling interests	(272)	(318)
Total equity	37,454	50,189
Liabilities and Equity, Total	$ 44,580	$ 63,376